Pfizer Inc. vs Novavax, Inc.: SG&A Expense Trends

SG&A Expense Trends: Pfizer Inc. vs Novavax, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Pfizer Inc. and Novavax, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. In contrast, Novavax has shown a dramatic increase, with expenses skyrocketing by over 2,200% from 2014 to 2023. This surge reflects Novavax's aggressive expansion and investment in its operations, particularly during the COVID-19 pandemic. While Pfizer's consistent spending underscores its established market position, Novavax's rising expenses highlight its growth ambitions. These trends offer a glimpse into the strategic priorities of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.